ATRA 8-K

Atara Biotherapeutics, Inc. (ATRA)

8-K 2026-08-12 For: 2026-08-12

Added on August 13, 2026


Delaware	001-36548	46-0920988
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1280 Rancho Conejo Blvd
Thousand Oaks, California		91320
(Address of Principal Executive Offices)		(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ATRA	The Nasdaq Stock Market LLC


Exhibit No.		Description

99.1		Press Release, dated August 12, 2026

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


			ATARA BIOTHERAPEUTICS, INC.

Date:	August 12, 2026	By:	/s/ Kevin G. Sarney
			Kevin G. Sarney Interim Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)


	June 30,			December 31,
	2026			2025
Assets
Current assets:
Cash and cash equivalents	$	3,221		$	8,482
Short-term investments		6,652			-
Accounts receivable		318			1,253
Other current assets		3,339			2,477
Total current assets		13,530			12,212
Property and equipment, net		41			73
Operating lease assets		6,688			7,064
Other assets		765			886
Total assets	$	21,024		$	20,235

Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$	824		$	127
Accrued compensation		699			1,271
Accrued research and development expenses		57			82
Deferred revenue		775			716
Liability related to the sale of future revenues – current portion		1,032			9,750
Other current liabilities		3,460			2,976
Total current liabilities		6,847			14,922
Operating lease liabilities – long-term		8,782			9,347
Liability related to the sale of future revenues – long-term		40,506			32,673
Other long-term liabilities		1,885			1,795
Total liabilities		58,020			58,737

Commitments and contingencies

Stockholders’ equity (deficit):
Common stock—$0.0001 par value, 500,000 shares authorized as of June 30, 2026 and December 31, 2025; 9,443 and 7,324 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively		1			1
Additional paid-in capital		1,993,849			1,983,361
Accumulated other comprehensive income (loss)		(2	)		1
Accumulated deficit		(2,030,844	)		(2,021,865	)
Total stockholders’ equity (deficit)		(36,996	)		(38,502	)
Total liabilities and stockholders’ equity (deficit)	$	21,024		$	20,235

FORM 8-K


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Commercialization revenue	$	630		$	17,575		$	1,146		$	115,724
Costs and operating expenses:
Cost of commercialization revenue		191			554			315			20,993
Research and development expenses		1,345			7,310			1,509			34,743
General and administrative expenses		3,814			6,514			7,411			17,989
Total costs and operating expenses		5,350			14,378			9,235			73,725
Income (loss) from operations		(4,720	)		3,197			(8,089	)		41,999
Other income (expense), net:
Interest income		78			143			132			379
Interest expense		(191	)		(972	)		(1,021	)		(1,989	)
Other income (expense), net		—			22			—			11
Total other income (expense), net		(113	)		(807	)		(889	)		(1,599	)
Income (loss) before provision for (benefit from) income taxes		(4,833	)		2,390			(8,978	)		40,400
Provision for (benefit from) income taxes		1			3			1			3
Net income (loss)	$	(4,834	)	$	2,387		$	(8,979	)	$	40,397
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities		(2	)		—			(3	)		(8	)
Comprehensive income (loss)	$	(4,836	)	$	2,387		$	(8,982	)	$	40,389

Basic (loss) earnings per common share	$	(0.32	)	$	0.20		$	(0.62	)	$	3.52
Diluted (loss) earnings per common share	$	(0.32	)	$	0.19		$	(0.62	)	$	3.49

Basic and diluted weighted-average shares outstanding		15,033			12,197			14,560			11,484
Diluted weighted-average shares outstanding		15,033			12,310			14,560			11,576